Sign in

Li Chen

Research Analyst at H.C. Wainwright

Li Chen is an Equity Research Associate at H.C. Wainwright & Co., specializing in biotechnology and life sciences sector analysis. Chen contributes to research coverage of emerging biotech companies, leveraging a blend of scientific expertise and financial analysis to support investment decisions, although specific performance metrics and company coverage are not publicly detailed. With a career focus on equity research in the life sciences, Chen provides crucial support in evaluating clinical data and market potential, having joined H.C. Wainwright following academic and industry experience in biomedical research. Professional credentials such as FINRA registration and securities licenses are not available in the public domain for Li Chen as of now.

Li Chen's questions to AFMD leadership

Li Chen's questions to AFMD leadership • Q3 2024

Question

Asked about the development strategy for AFM28, including potential acceleration and positioning (frontline vs. later-line), and the rationale for choosing between unengineered NK cells versus CAR-NK cells for a combination therapy.

Answer

The company's preferred strategy for AFM28 is to first consolidate the monotherapy signal for a potential accelerated approval path in later-line AML, which is faster than a frontline trial. For combinations, they prefer using an allogeneic NK cell product over CAR-NKs, citing lower cost, simpler manufacturing, and the ability to recruit the patient's own NK cells for a dual attack.

Ask Fintool Equity Research AI